Insulin Family intermediate
Insulin Injection Site Lipohypertrophy
Lipodystrophy at insulin injection sites caused by localized anabolic effects leading to erratic absorption.
By Encyclopeptide Editorial | 1 min read
insulin lipohypertrophy injection-site complication diabetes
Overview
Lipohypertrophy is the most common injection-related complication of insulin therapy, occurring in 30-60% of patients due to local anabolic effects on subcutaneous adipose tissue.
Clinical Consequences
- Erratic insulin absorption (25-50% variability)
- Unexplained glycemic variability
- Increased insulin requirements
- Poor glycemic control despite appropriate dosing
Prevention and Management
- Systematic site rotation at every injection
- Regular palpation of injection sites
- Education on proper injection technique
Chemical Identity
| Property | Value |
|---|---|
| Name | Insulin Injection Site Lipohypertrophy |
| Category | Insulin Family |
References
- Encyclopeptide Database. “Insulin Injection Site Lipohypertrophy” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Insulin Injection Site Lipohypertrophy with interactive quizzes on Wikipept.
Take a Quiz on Wikipept